BURDEN OF ILLNESS IN THE MANAGEMENT OF AGE-RELATED MACULAR DEGENERATION- FINDINGS FROM A TIME-AND-MOTION STUDY
Author(s)
Williams ZY1, Prenner JL2, Halperin LS3, Hogue S4, Seibert R1
1Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA, 2Robert Wood Johnson Medical School, New Brunswick, NJ, USA, 3Charles E. Schmidt College of Medicine, Fort Lauderdale, FL, USA, 4RTI-Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: Neovascular age-related macular degeneration (NVAMD) is a costly, debilitating, and progressive disease that profoundly impacts patients’ visual acuity. NVAMD is the leading cause of blindness in the developed world. This time-and-motion study investigated the physician, patient, and caregiver time burden associated with the management of patients with NVAMD in the United States. METHODS: Quantitative research was conducted in June 2011 and August 2012. A survey was conducted with 57 retina specialists who administered ≥ 50 vascular endothelial growth factor (VEGF)-inhibitor injections per month; 56 of these physicians completed records (patient history and diaries) for ≤ 5 patients scheduled for an office visit within the next 3 weeks for an anti-VEGF injection or monitoring. Additionally, a survey was administered to 75 patients with NVAMD who were aged ≥ 50 years and had received ≥ 1 anti-VEGF injection in the past 6 months. Furthermore, telephone interviews were conducted with 13 caregivers of patients with NVAMD. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PSS24
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Sensory System Disorders